Search
Search
About
Log in
Join
Experiences with
Castration
Posts
Communities
1,150 public posts
Filter results
********************Testosterone & PSA********************
ADT for 24weeks (2020/05/31)+(2020/08/24)Lupron Depot 22.5mg/12weeks X 2 VNAT-RT 3Gy X 20 fx (2020/06/08 to 2020/07/07) *Testosterone Level under-
castration
= <0.7nmol/L - <20.189ng/dL [u]
********************Testosterone********************
[/u] *Pre-ADT = 10.30nmol/L - 294.19ng/dL (2020
ADT for 24weeks (2020/05/31)+(2020/08/24)Lupron Depot 22.5mg/12weeks X 2 VNAT-RT 3Gy X 20 fx (2020/06/08 to 2020/07/07) *Testosterone Level under-
castration
= <0.7nmol/L - <20.189ng/dL [u]
********************Testosterone********************
[/u] *Pre-ADT = 10.30nmol/L - 294.19ng/dL (2020
doc1947g
in
Prostate Cancer Network
2 years ago
After months of urinary tract problems, I was finally diagnosed with Stage 4 Advanced Prostate Cancer with a Gleason score of 9 by the VA
I am not eager to dash headlong into the
castration
-resistant marketplace. Has anyone here had a similar experience? If so, what did you try and what were the results? ###
I am not eager to dash headlong into the
castration
-resistant marketplace. Has anyone here had a similar experience? If so, what did you try and what were the results? ###
diamondrn
in
Advanced Prostate Cancer
3 years ago
High intratumoral dihydrotestosterone is associated with antiandrogen resistance in VCaP prostate cancer xenografts in castrated mice
PMID: 35573198 PMCID: PMC9097697 DOI: 10.1016/j.isci.2022.104287 Abstract Antiandrogen treatment resistance is a major clinical concern in
castration
-resistant prostate cancer (CRPC) treatment.
PMID: 35573198 PMCID: PMC9097697 DOI: 10.1016/j.isci.2022.104287 Abstract Antiandrogen treatment resistance is a major clinical concern in
castration
-resistant prostate cancer (CRPC) treatment.
pjoshea13
in
Advanced Prostate Cancer
2 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
PSA is increasing with Docetaxel, what should we do now ?
Updated Diagnosi: Metastatic
Castration
-Resistant Prostate Cancer (mCRPC). he stoped Casodex 50mg (bicalutamide) and switched to Zytiga 500mg (Abiraterone acetate), 1000mg daily along with Solupred 5mg (Prednisolone) only 5mg daily.
Updated Diagnosi: Metastatic
Castration
-Resistant Prostate Cancer (mCRPC). he stoped Casodex 50mg (bicalutamide) and switched to Zytiga 500mg (Abiraterone acetate), 1000mg daily along with Solupred 5mg (Prednisolone) only 5mg daily.
mgaa
in
Advanced Prostate Cancer
2 years ago
ASCO GU 2022: PROpel Suggests Adding Olaparib to Abiraterone Improves Outcomes In CRPC Regardless of Repair Status
“This benefit led to what I think is the longest radiographic PFS we have seen to date in metastatic
castration
-resistant prostate cancer, beyond 2 years. This benefit was seen irrespective of HRR mutational status.
“This benefit led to what I think is the longest radiographic PFS we have seen to date in metastatic
castration
-resistant prostate cancer, beyond 2 years. This benefit was seen irrespective of HRR mutational status.
Balsam01
in
Advanced Prostate Cancer
2 years ago
Androgen Receptor [AR] Axis Therapies
Darolutamide in nonmetastatic,
castration
-resistant prostate cancer. N Engl J Med. 2019;380:1235-1246. de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic
castration
-resistant prostate cancer. N Engl J Med. 2020;382:2091-2102. Wu JN, Fish KM, Evans CP, Devere White RW, Dall'Era MA.
Darolutamide in nonmetastatic,
castration
-resistant prostate cancer. N Engl J Med. 2019;380:1235-1246. de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic
castration
-resistant prostate cancer. N Engl J Med. 2020;382:2091-2102. Wu JN, Fish KM, Evans CP, Devere White RW, Dall'Era MA.
pjoshea13
in
Advanced Prostate Cancer
3 years ago
Cardiotoxicity of Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
"Further, the risk of hospitalization for heart failure was greater in abiraterone acetate (HR 2.88 ...)." https://www.urotoday.com/conference-highlights/aua-2021-program/aua-2021-prostate-cancer/131969-aua-2021-comparison-of-the-cardiotoxicity-of-abiraterone-and-enzalutamide-in-metastatic-
castration
-resistant-prostate-cancer-using-real-world-data.html
"Further, the risk of hospitalization for heart failure was greater in abiraterone acetate (HR 2.88 ...)." https://www.urotoday.com/conference-highlights/aua-2021-program/aua-2021-prostate-cancer/131969-aua-2021-comparison-of-the-cardiotoxicity-of-abiraterone-and-enzalutamide-in-metastatic-
castration
-resistant-prostate-cancer-using-real-world-data.html
pjoshea13
in
Advanced Prostate Cancer
3 years ago
Dasatinib
There was a 2009 paper [5]: "
Phase II Study of Dasatinib in Patients with Metastatic
-Resistant Prostate Cancer" I have pasted in the interesting Discussion section [5].
There was a 2009 paper [5]: "
Phase II Study of Dasatinib in Patients with Metastatic
-Resistant Prostate Cancer" I have pasted in the interesting Discussion section [5].
pjoshea13
in
Advanced Prostate Cancer
3 years ago
Gut Bacteria again.
Ablation of the gut microbiota by antibiotic therapy delayed the emergence of
castration
resistance even in immunodeficient mice. Fecal microbiota transplantation (FMT) from CRPC mice and patients rendered mice harboring prostate cancer resistant to
castration
.
Ablation of the gut microbiota by antibiotic therapy delayed the emergence of
castration
resistance even in immunodeficient mice. Fecal microbiota transplantation (FMT) from CRPC mice and patients rendered mice harboring prostate cancer resistant to
castration
.
pjoshea13
in
Advanced Prostate Cancer
3 years ago
PRINT: Prostate cancer intensive, non-cross reactive therapy for CRPC (trial by Icahn School of Medicine)
Rapid cycling of available CRPC therapies may eliminate
castration
-resistant clones in a subset of patients, a concept warranting further preclinical and clinical evaluation
Rapid cycling of available CRPC therapies may eliminate
castration
-resistant clones in a subset of patients, a concept warranting further preclinical and clinical evaluation
noahware
in
Advanced Prostate Cancer
3 years ago
Neuroendocrine Prostate Cancer [NEPC]
LTL331 is an interesting PDX model that alters the phenotype from adenocarcinoma to NEPC (LTL331R) after
castration
of the host mouse. LTL331 follows the clinical course of trans-differentiation, with initial tumor shrinkage upon
castration
, and rapid re-growth without a rise in PSA levels.
LTL331 is an interesting PDX model that alters the phenotype from adenocarcinoma to NEPC (LTL331R) after
castration
of the host mouse. LTL331 follows the clinical course of trans-differentiation, with initial tumor shrinkage upon
castration
, and rapid re-growth without a rise in PSA levels.
pjoshea13
in
Advanced Prostate Cancer
3 years ago
Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing
Androgen deprivation therapy and chemotherapy are usually reserved for advanced disease or biochemical recurrence, such as
castration
-resistant prostate cancer (CRPC), but they are not considered curative because PCa cells eventually develop drug resistance.
Androgen deprivation therapy and chemotherapy are usually reserved for advanced disease or biochemical recurrence, such as
castration
-resistant prostate cancer (CRPC), but they are not considered curative because PCa cells eventually develop drug resistance.
Scout4answers
in
Advanced Prostate Cancer
2 years ago
Interesting article from a Duke study in 2018 -- Smell Receptors Fuel Prostate Cancer Progression. I may be experiencing this, now.
They found that activating an olfactory receptor called OR51E2 in prostate cancer cells caused the cancer to morph into the more aggressive, ‘
castration
-resistant’ form of the disease.
They found that activating an olfactory receptor called OR51E2 in prostate cancer cells caused the cancer to morph into the more aggressive, ‘
castration
-resistant’ form of the disease.
Skipper238
in
Advanced Prostate Cancer
2 years ago
How diet and gut microbiome can affect castration sensitive vs resistance
https://www.sciencedaily.com/releases/2021/10/211007145906.htm
https://www.sciencedaily.com/releases/2021/10/211007145906.htm
GeorgeGlass
in
Advanced Prostate Cancer
3 years ago
Not BAT, but ...
However, most patients eventually develop the
castration
-resistant prostate cancer (CRPC) that progresses rapidly despite ongoing systemic androgen deprivation.
However, most patients eventually develop the
castration
-resistant prostate cancer (CRPC) that progresses rapidly despite ongoing systemic androgen deprivation.
pjoshea13
in
Advanced Prostate Cancer
2 years ago
Daralutamide and Survival in Metastatic, Hormone Sensitive Prostate Cancer
., for the ARASENS Trial Investigators* Abstract BACKGROUND Darolutamide is a potent androgen-receptor inhibitor that has been associated with increased overall survival among patients with nonmetastatic,
castration
-resistant prostate cancer.
., for the ARASENS Trial Investigators* Abstract BACKGROUND Darolutamide is a potent androgen-receptor inhibitor that has been associated with increased overall survival among patients with nonmetastatic,
castration
-resistant prostate cancer.
Graham49
in
Advanced Prostate Cancer
2 years ago
177Lu-PSMA-617 versus docetaxel in chemotherapy-naïve mCRPC: a randomized, controlled, phase 2 non inferiority trial.
treatment of mCRPC and could, thus, be potentially employed earlier in the disease course rather than being solely reserved for advanced end-stage disease." https://www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/134156-177lu-psma-617-versus-docetaxel-in-chemotherapy-naive-metastatic-
castration
-resistant-prostate-cancer-a-randomized-controlled-phase
treatment of mCRPC and could, thus, be potentially employed earlier in the disease course rather than being solely reserved for advanced end-stage disease." https://www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/134156-177lu-psma-617-versus-docetaxel-in-chemotherapy-naive-metastatic-
castration
-resistant-prostate-cancer-a-randomized-controlled-phase
tango65
in
Advanced Prostate Cancer
3 years ago
ARASENS Trial
., for the ARASENS Trial Investigators* Abstract BACKGROUND Darolutamide is a potent androgen-receptor inhibitor that has been associated with increased overall survival among patients with nonmetastatic,
castration
-resistant prostate cancer.
., for the ARASENS Trial Investigators* Abstract BACKGROUND Darolutamide is a potent androgen-receptor inhibitor that has been associated with increased overall survival among patients with nonmetastatic,
castration
-resistant prostate cancer.
Scout4answers
in
Advanced Prostate Cancer
2 years ago
Metabolic syndrome and long-term prostate cancer outcomes after radical prostatectomy. Presented at: AUA 2021, held September 10-13, 2021
“This suggests there may metabolic factors at play in promoting the transition from the
castration
-sensitive to
castration
-resistant disease state.”
“This suggests there may metabolic factors at play in promoting the transition from the
castration
-sensitive to
castration
-resistant disease state.”
Graham49
in
Advanced Prostate Cancer
3 years ago
In vitro support for Simvastatin
Combination therapy with novel androgen receptor antagonists and statin for
castration
-resistant prostate cancer.
Combination therapy with novel androgen receptor antagonists and statin for
castration
-resistant prostate cancer.
cigafred
in
Advanced Prostate Cancer
3 years ago
1
...
18
19
20
...
58
Next page
10
20
30
40
50
Filter results
Clear filters
Posted in
All communities
Advanced Prostate Cancer
1024 results
Fight Prostate Cancer
70 results
Prostate Cancer Network
25 results
View top 10 communities
Sort by
Most Relevant
Newest